Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide before focal therapy versus focal therapy alone for localized prostate cancer
ISRCTN19290230Phase 3Recruiting
- Sponsor
- Imperial College London
- Start
- May 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of apalutamide in prostate cancer (PCa) (2 arms), sponsored by Imperial College London. Primary endpoints: Recruitment rate per centre per month, Acceptance of randomisation and compliance to allocated arm and 1 more. Started May 2026; status: recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ISRCTN19290230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN19290230.